BioSpace News Archive

Q2-2020 Key Results Revenue (millions) $ 84.8 • Newborn Care revenue increased 1% compared to second quarter last year • Reduced debt by $13.0 million during the quarter • NICVIEW II released during the quarter GAAP loss per share $ 0.26 Non-GAAP loss per share $ 0.13

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2020 financial results on Thursday, August 6, 2020, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, August 6, 2020 at 4:30 p.m. (ET)/1:30 p.m. (PT). The live audio webcast may be accessed through the “Events &am

Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, today announced the closing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $16.00 per share on July 28, 2020 and the closing of the sale of 1,050,000 additional shares of common stock on July 30, 2020 following the exercise in f

Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021

OPKO Health, Inc. reports business highlights and financial results for the three months ended June 30, 2020.

Increased Total Revenue 1% Year-over-Year to $30.7 Million Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations Launching Seven FDA-Cleared Orthopedic and Sports Medicine Products Through Q3 2020

Teleflex Incorporated announced that 200,000 patients have been treated with the minimally invasive UroLift® System for benign prostatic hyperplasia worldwide.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on upcoming milestones for its lead product candidate remestemcel-L, and an activity report for the fourth quarter ended June 30, 2020.

Women receiving standard treatment in New York City for ovarian, uterine, and cervical cancers are not at increased risk of being hospitalized for or dying from COVID-19 due to their cancer, a new study shows.

Aurinia Pharmaceuticals Inc. announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close.